Physician profile
Jerod C Smith
NPI 1669880993
$5,880.34
in general payments reported to CMS, 2019-2025
28 companies · $684 in 2025
The $684 reported for 2025 was more than what 82% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $206 · 2022: $1,696 · 2023: $1,906 · 2024: $1,389 · 2025: $684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,979.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,978.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $581.88 | 2022-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $573.03 | 2022-2025 | |
| Tactile Systems Technology INC | $525.49 | 2021-2025 | Flexitouch Plus, Entre Plus, Nimbl |
| Amgen INC. | $516.69 | 2022-2025 | Repatha, Repatha |
| Merck Sharp & Dohme LLC | $490.55 | 2022-2025 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $439.03 | 2022-2025 | Camzyos, Eliquis |
| Pfizer INC. | $368.78 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $343.44 | 2022-2025 | |
| Cvrx, INC. | $314.15 | 2022-2024 | Barostim Neo System |
| Boehringer Ingelheim Pharmaceuticals, INC. | $279.04 | 2022-2025 | Jardiance |
| Astrazeneca Pharmaceuticals Lp | $259.73 | 2022-2024 | Brilinta, Wainua, Farxiga |
| Daiichi Sankyo INC. | $178.28 | 2022-2023 | Injectafer |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $169.57 | 2022-2024 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $134.55 | 2022-2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $97.56 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $93.73 | 2024-2025 | Impella |
| Sanofi-Aventis U.S. LLC | $88.59 | 2022-2024 | |
| Amarin Pharma, INC. | $81.77 | 2022-2023 | |
| Boston Scientific Corporation | $69.51 | 2023-2025 | Cds - Mct/Cem Monitoring, Watchman Access System, Watchman Flx |
| Heartflow, INC. | $60.58 | 2024-2025 | |
| Convatec INC. | $51.52 | 2024 | |
| Kerecis Limited | $39.66 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose |
| Reprise Biomedical, INC. | $28.10 | 2024 | Miro3d |
| Smith+Nephew, INC. | $23.31 | 2024 | Collagenase Santyl |
| Kiniksa Pharmaceuticals, Ltd. | $22.34 | 2023 | Arcalyst |
| Nevro Corp. | $21.18 | 2023 | Senza |
| Organogenesis INC. | $19.50 | 2023 | Puraply |
| Biowound Solutions, INC. | $8.78 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jerod Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.